 SAN DIEGO, Nov. 03, 2022 GLOBE NEWSWIRE -- Oncternal Therapeutics, Inc. Nasdaq: ONCT, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim clinical data from the ongoing Phase 12 Study CIRM-0001 will be presented in an Oral Session at the American Society of Hematology ASH Annual Meeting and Exposition taking place on December 10-13, 2022, in New Orleans, Louisiana. In the CIRM-0001 study, zilovertamab, an investigational anti-ROR1 monoclonal antibody, is being evaluated in combination with ibrutinib in patients with mantle cell lymphoma MCL, chronic lymphocytic leukemia CLL and in a recently opened cohort for patients with marginal zone lymphoma MZL. The clinical trial is being conducted in collaboration with the University of California San Diego UC San Diego and has been partially funded by the California Institute for Regenerative Medicine CIRM. 